Ixekizumab (Taltz®) for psoriatic arthritis

Assessment Status Rapid Review Complete
Drug Ixekizumab
Brand Taltz®
Indication For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies
Assessment Process
Rapid review commissioned 16/10/2018
Rapid review completed 19/11/2018
Rapid review outcome Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013